Fimepinostat (CUDC-907)

For research use only. Not for use in humans.

目录号:S2759 中文名称:非美诺司他

Fimepinostat (CUDC-907) Chemical Structure

CAS No. 1339928-25-4

CUDC-907是一种PI3K和HDAC双重抑制剂,作用于PI3KαHDAC1/2/3/10IC50分别为19 nM和1.7 nM/5 nM/1.8 nM/2.8 nM。CUDC-907 在乳腺癌细胞中可诱导细胞周期阻滞与凋亡。Phase 1。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4500.71 现货
RMB 2207.14 现货
RMB 8763.3 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Fimepinostat (CUDC-907)发表文献28篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 CUDC-907是一种PI3K和HDAC双重抑制剂,作用于PI3KαHDAC1/2/3/10IC50分别为19 nM和1.7 nM/5 nM/1.8 nM/2.8 nM。CUDC-907 在乳腺癌细胞中可诱导细胞周期阻滞与凋亡。Phase 1。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
HDAC10 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
1.7 nM 1.8 nM 2.8 nM 5.0 nM 5.4 nM
体外研究

PI3K/HDAC Inhibitor 抑制其他PI3K亚型,如 PI3Kβ, PI3Kγ, PI3Kδ和 PI3KɑE545K , IC50 分别为 54, 311, 39 和62 nM。而且, PI3K/HDAC Inhibitor 也抑制HDAC亚型HDAC8, HDAC6 和 HDAC11,IC50分别为191, 27 和 5.4 nM。此外, PI3K/HDAC Inhibitor 低效抑制其他类型 HDAC 酶活性。PI3K/HDAC Inhibitor 抑制一系列B细胞淋巴瘤生长,如Granta 519, DOHH2, RL, Pfeiffer, SuDHL4, Daudi 和 Raji,IC50 分别为 7, 1, 2, 4, 3, 15 和 9 nM。PI3K/HDAC Inhibitor 也阻断 骨髓瘤增殖,如RPMI8226, OPM-2 和 ARH77,IC50分别为 2, 1 和5 nM。PI3K/HDAC Inhibitor 作用于多发性骨髓瘤和B细胞淋巴瘤,具有有效抗癌活性。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Glioma cells (HF2885) MmXtR5l1d3SxeHnjbZR6KGG|c3H5 NY\P[npIPzJiaB?= MoTrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gS4xqd22jIHPlcIx{KCiKRkK4PFUqKGGodHXyJFczKGi{czDifUBE\WyudHn0[ZJIdG9iYYPzZZktKEWFNUC9NE44KG6P M4XDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
human Glioma cells (HF3013) NFPU[JBEgXSxdH;4bYNqfHliYYPzZZk> M1fnR|czKGh? Mo\uR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gS4xqd22jIHPlcIx{KCiKRkOwNVMqKGGodHXyJFczKGi{czDifUBE\WyudHn0[ZJIdG9iYYPzZZktKEWFNUC9NE44KG6P M2qy[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
human Glioma cells (HF2876)  MXPDfZRwfG:6aXPpeJkh[XO|YYm= Mn\XO|IhcA>? M3vkO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yPFc3MSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?= MlfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
human Glioma cells (HF2790)  NGXVbGFEgXSxdH;4bYNqfHliYYPzZZk> MWi3NkBp NEPGdplEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIdGmxbXGgZ4VtdHNiKFjGNlc6OCliYX\0[ZIhPzJiaILzJIJ6KEOnbHz0bZRmekeubzDhd5NigSxiRVO1NF0xNjdibl2= NVqxPHpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
human Glioma cells (HF2476) M3zyXWN6fG:2b4jpZ4l1gSCjc4PhfS=> NEfXPJI4OiCq NFX3[XdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIdGmxbXGgZ4VtdHNiKFjGNlQ4PiliYX\0[ZIhPzJiaILzJIJ6KEOnbHz0bZRmekeubzDhd5NigSxiRVO1NF0xNjdibl2= NYnwSWFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
human Glioma cells (HF2381) MlTIR5l1d3SxeHnjbZR6KGG|c3H5 MkPpO|IhcA>? MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDHcIlwdWFiY3XscJMhMEiIMkO4NUkh[W[2ZYKgO|IhcHK|IHL5JGNmdGy2aYTldmdtdyCjc4PhfUwhTUN3ME2wMlchdk1? M4\CNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
human Glioma cells (HF2303) NVe2VFN5S3m2b4TvfIlkcXS7IHHzd4F6 NYG2[lI1PzJiaB?= M3PtO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdtcW:vYTDj[YxteyBqSF[yN|A{MSCjZoTldkA4OiCqcoOgZpkhS2WubITpeIVzT2yxIHHzd4F6NCCHQ{WwQVAvPyCwTR?= NU\IR3NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
MV4-11 NH3RcFVEgXSxdH;4bYNqfHliYYPzZZk> Mo\pNlQhcHK| MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiPUCuNFAxPDQQvF2u MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O|Y9N2F-
Sf9 NE\Eb4hHfW6ldHnvckBie3OjeR?= MXyxOUBucW6| NGrmO2lKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|LYTh[4dm\CCqdX3hckBz\WOxbXLpcoFvfCCKRFHDN{9PS0:UMjCoN|k2KHSxIES4PUBz\XOrZIXld{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiQXOtdIVxfGmmZT3BUWMh[XNic4Xid5Rz[XSnIHHzd4V{e2WmIHHzJJJmdGWjc3Wgc4YhSU2FIIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDzeYJ{fHJuIE2wMlAxOTkQvF2u NUTzOGx7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
Sf9 MlfYSpVv[3Srb36gZZN{[Xl? M33nbFE2KG2rboO= NFnJS3NKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyOCCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6|ZXP0JHNnQSClZXzsd{B2e2mwZzDBZ{1x\XC2aXTlMWFOSyCjczDzeYJ{fHKjdHWgZZN{\XO|ZXSgZZMhemWuZXHz[UBw\iCDTVOgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBie3OjeTygQVAvODB{ON88UU4> M2jORVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi2Olc3Lz5{N{G4OlY4PjxxYU6=
Sf9 MoGzSpVv[3Srb36gZZN{[Xl? M176[FE2KG2rboO= M1LVbmlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5icnXjc41jcW6jboSgTGRCSzJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBU\jliY3XscJMhfXOrbnegRYMueGWydHnk[U1CVUNiYYOgd5Vje3S{YYTlJIF{e2W|c3XkJIF{KHKnbHXhd4Uhd2ZiQV3DJJBz\WmwY4XiZZRm\CCob4KgNVUhdWmwczDmc4xtd3enZDDifUB{fWK|dILheIUh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDmcJVwemW|Y3XuZ4Uh[SxiPUCuNFA2|ryPLh?= NFu3N5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9 NHvzNGlHfW6ldHnvckBie3OjeR?= MmTJNVUhdWmwcx?= M4SyN2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5icnXjc41jcW6jboSgTGRCSzFzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KHW|aX7nJGFkNXCncITp[IUuSU2FIHHzJJN2[nO2cnH0[UBie3Onc4Pl[EBieyC{ZXzlZZNmKG:oIFHNR{BxemWrbnP1ZoF1\WRiZn;yJFE2KG2rboOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKCxiPUCuNFA2PM7:TT6= Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O|YoRjJ5MUi2Olc3RC:jPh?=
A2780S MX3DfZRwfG:6aXPpeJkh[XO|YYm= M33oOlI1KGi{cx?= MnPYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDCVIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIE2wMlAxPjF3zszNMi=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O|Y9N2F-
HCT116 NWj0bVF1S3m2b4TvfIlkcXS7IHHzd4F6 MnfRNlQhcHK| M3\XNmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDC9NE4xODd|NN88UU4> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O|Y9N2F-
Sf9 M{PxdWZ2dmO2aX;uJIF{e2G7 M{fRW|YxKG2rboO= NXPzTYV1UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRicEGxNEBidHCqYT;1cpRi\2enZDDwPFUh[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNidYPpcochWEl8M2DTJIF{KHO3YoP0doF1\SCrbnP1ZoF1\WRiZn;yJFYxKG2rboOgZpkhSUSSLVfsc{BtfW2rbnXzZ4Vv[2ViYYPzZZktKD1yLkCxPe69VS5? MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O|YoRjJ5MUi2Olc3RC:jPh?=
Sf9 MYPGeY5kfGmxbjDhd5NigQ>? M376d|E2KG2rboO= MoGxTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6|ZXP0JHNnQSClZXzsd{B2e2mwZzDBZ{1x\XC2aXTlMWFOSyCjczDzeYJ{fHKjdHWgZZN{\XO|ZXSgZZMhemWuZXHz[UBw\iCDTVOgdJJmcW6ldXLheIVlKG[xcjCxOUBucW6|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBiNCB;MD6wNlfPxE1w NU\3elRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
Sf9 MlLWSpVv[3Srb36gZZN{[Xl? MYCyJIhzew>? MVnJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHTlcJRiN3WwdHHn[4VlKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGmwY4XiZZRm\CCob4KgNkBpenNiYomgb4lv[XOnLXfsc{Bie3OjeTygQVAvODN7zszNMi=> NGqzZVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4OlY4Pid-MkexPFY3PzZ:L3G+
Sf9 MXnGeY5kfGmxbjDhd5NigQ>? NV3Ocm8yOSCqch?= MYXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKHBzMUDi[ZRiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCDRGCt[4xwemWjZ3XuJIF{e2G7LDC9NE4xPTUQvF2u MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O|Y9N2F-
A2780S Mm\4SpVv[3Srb36gZZN{[Xl? MkTmOkBpenN? MX;Jcohq[mm2aX;uJI9nKEiGQVOxM|IwOyCrbjDoeY1idiCDMke4NHMh[2WubIOgZZN{\XO|ZXSgZZMhcGm|dH;u[UBJOyCjY3X0fYxifGmxbjDpcoN2[mG2ZXSg[o9zKDZiaILzJIJ6KGO7dH;icI91KGG|c3H5MEA:OC5zMk[yOe69VS5? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6Nk[3Okc,OjdzOE[2O|Y9N2F-
Sf9 NX3md5NETnWwY4Tpc44h[XO|YYm= NYPs[ok5OTVibXnudy=> NFvsT|NKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhUGm|LYTh[4dm\CCqdX3hckBz\WOxbXLpcoFvfCCKRFHDPEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCDYz3w[ZB1cWSnLVHNR{BieyC|dXLzeJJifGViYYPz[ZN{\WRiYYOgdoVt\WG|ZTDv[kBCVUNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBuIE2wMlE6Oc7:TT6= NXfXc5RrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
A2780S Mm\kSpVv[3Srb36gZZN{[Xl? NFzueIQ3KGi{cx?= Ml7nTY5pcWKrdHnvckBw\iCKRFHDOkBqdiCqdX3hckBCOjd6MGOgZ4VtdHNiYYPz[ZN{\WRiYYOgeJVjfWyrbjDhZ4V1gWyjdHnvckBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IHP5eI9jdG:2IHHzd4F6NCB;MD6yNlE4Pc7:TT6= MoH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O|YoRjJ5MUi2Olc3RC:jPh?=
Sf9 MUHGeY5kfGmxbjDhd5NigQ>? NXrBZm5KOTVibXnudy=> NX3afWt3UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC:FLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzRiKE[yO{B1dyBzMEi0JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCDYz3w[ZB1cWSnLVHNR{BieyC|dXLzeJJifGViYYPz[ZN{\WRiYYOgdoVt\WG|ZTDv[kBCVUNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2LDC9NE41ODoQvF2u M1v6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi2Olc3Lz5{N{G4OlY4PjxxYU6=
Sf9 NWXTWZpuTnWwY4Tpc44h[XO|YYm= NYHBeFhUOTVibXnudy=> M3TJUWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QufGGpZ3XkJIh2dWGwIILlZ49u[mmwYX70JGhFSUN5IDi1NVghfG9iZX7kJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCDYz3w[ZB1cWSnLVHNR{BieyC|dXLzeJJifGViYYPz[ZN{\WRiYYOgdoVt\WG|ZTDv[kBCVUNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fSxiPUCuOFI3|ryPLh?= M2fuflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi2Olc3Lz5{N{G4OlY4PjxxYU6=
Sf9 MorKSpVv[3Srb36gZZN{[Xl? M4PFcVE2KG2rboO= MYXJcohq[mm2aX;uJI9nKENvdHXycYlv[WxiSHnzMZRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQSBqNkC0JJRwKDFyNk[gdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiU3[5JINmdGy|IIXzbY5oKEGlLYDldJRq\GVvQV3DJIF{KHO3YoP0doF1\SCjc4Pld5Nm\CCjczDy[Yxm[XOnIH;mJGFOSyCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZMtKD1yLkW1OO69VS5? NWLERVRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFY3PzZpPkK3NVg3Pjd4PD;hQi=>
Sf9 M3\PVmZ2dmO2aX;uJIF{e2G7 NHfRSXAyPSCvaX7z MknzTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IGPmPUBk\WyuczD1d4lv\yCDYz3w[ZB1cWSnLVHNR{BieyC|dXLzeJJifGViYYPz[ZN{\WRiYYOgdoVt\WG|ZTDv[kBCVUNicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiPUCuOlc1|ryPLh?= Ml\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOE[2O|YoRjJ5MUi2Olc3RC:jPh?=
Sf9 MVvGeY5kfGmxbjDhd5NigQ>? Mlm4TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhWEl|SzDwNVEx[WyyaHGveY51[WepZXSgdFg2[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCCVZkmgZ4VtdHNiYomgRWRRNUeubzDseY1qdmW|Y3XueEBie3OjeTygQVAvODF7zszNMi=> Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUSyOVYoRjJ6NEm0NlU3RC:jPh?=
Sf9 NInPSXlHfW6ldHnvckBie3OjeR?= NWTXSG0zUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiUFmzT{BxOTFyZHXseIEwfW62YXfn[YQheDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgZpkhSUSSLVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhRTBwMEO5{txONg>? MojOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUSyOVYoRjJ6NEm0NlU3RC:jPh?=
Sf9 MkTvSpVv[3Srb36gZZN{[Xl? NF:0bYFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKGi3bXHuJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCSSUPLJJAyOTCkZYThM5VvfGGpZ3XkJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiU3[5JINmdGy|IHL5JGFFWC2JbH:gcJVucW6nc3PlcpQh[XO|YYmsJF0xNjB3NN88UU4> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7NEK1Okc,Ojh2OUSyOVY9N2F-
TC32 M1i5U5FJXFNiYYPzZZk> NW\VOJU6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= NYSyV49XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY MnXndWhVWyCjc4PhfS=> Mn;JdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MoW0dWhVWyCjc4PhfS=> MnrqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NIXPUFNyUFSVIHHzd4F6 NWG4cXZkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= NGmxRYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC M3vSXpFJXFNiYYPzZZk> MlntdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= Mme0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NXvxNWtCeUiWUzDhd5NigQ>? MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NFjyWZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 NV\1NIk6eUiWUzDhd5NigQ>? MnPkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NUDONmJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS NYfGNnZQeUiWUzDhd5NigQ>? NFrpO3lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz NYHSOWFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MlPsdWhVWyCjc4PhfS=> M3vpU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= NILBeFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NUnDO45SeUiWUzDhd5NigQ>? M13xOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz M4D0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NWLJe45{eUiWUzDhd5NigQ>? MnTwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= M1TBb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NF\mS45yUFSVIHHzd4F6 NX;s[JNueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MkfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NEjoeXRyUFSVIHHzd4F6 M{XSWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M4rPVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NX3ufXZoeUiWUzDhd5NigQ>? NX6zOJl6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= NVvNV5lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NV3Fe3FTeUiWUzDhd5NigQ>? M{HnTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NHTwO|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MnXYdWhVWyCjc4PhfS=> Mo[3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ M3HHclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) NVm4c2t3eUiWUzDhd5NigQ>? NXH1e|Q{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NHzhZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 MUDxTHRUKGG|c3H5 NYrRNldseUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= MmT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 M{P3S5FJXFNiYYPzZZk> NEHLdWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= M13IeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NI[wVGtyUFSVIHHzd4F6 M4[0fZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>? MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NW\JflRieUiWUzDhd5NigQ>? NFvxRY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? MkfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 Mn;qdWhVWyCjc4PhfS=> M{j3cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ M2XzN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NYK1U4lneUiWUzDhd5NigQ>? NWKxbnVneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NXzEeZF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY MmHYdWhVWyCjc4PhfS=> Mlm4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsdy=> MlX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) NGHVbYNyUFSVIHHzd4F6 MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=> NHHhSJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS MmLDdWhVWyCjc4PhfS=> NXnNbIx7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MYHxTHRUKGG|c3H5 NVzaO40zeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD Ml20dWhVWyCjc4PhfS=> NFnubG1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 NWPHdFgxeUiWUzDhd5NigQ>? NF7COpZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{ NX\yc3JoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NWX3eFFYeUiWUzDhd5NigQ>? MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz NF72NII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MYfxTHRUKGG|c3H5 NGDMbGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| MnKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NVzE[Hp7eUiWUzDhd5NigQ>? MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? NGHpSZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NYPYWVRUeUiWUzDhd5NigQ>? NWD4cphleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NE\xb5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Daoy MV7xTHRUKGG|c3H5 MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJGRid3liY3XscJM> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Sf9 NYrLcJhiTnWwY4Tpc44h[XO|YYm= M{fkTGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBIW1RvdHHn[4VlKHBzMUDhcJBp[S:3boTh[4dm\CCodXzsMYxmdme2aDDwPFVidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKGK7IFHEVE1odG9ibIXtbY5me2OnbnPlJIF{e2G7LDC9NE4xOToQvF2u NV7nZo1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0NVg4PjZpPkOwOFE5PzZ4PD;hQi=>
Sf9 MX;GeY5kfGmxbjDhd5NigQ>? M4q3VmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscE1t\W6pdHigUk11\XKvaX7hcEBIW1RvdHHn[4VlKHBzMUDk[Yx1[S:3boTh[4dm\CCodXzsMYxmdme2aDDwPFVidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKFCLUEKgZZMhe3Wkc4TyZZRmKGK7IFHEVE1odG9ibIXtbY5me2OnbnPlJIF{e2G7LDC9NE4xOzoQvF2u MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODRzOEe2Okc,OzB2MUi3OlY9N2F-
Sf9 NHzC[lRHfW6ldHnvckBie3OjeR?= MmjhTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGdUXC22YXfn[YQheDFzMHLleIEwfW62YXfn[YQh\nWubD3s[Y5ofGhicEi1ZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBjgSCDRGCt[4xwKGy3bXnu[ZNk\W6lZTDhd5NigSxiPUCuNFU1|ryPLh?= M{\oPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEG4O|Y3Lz5|MESxPFc3PjxxYU6=
Sf9 MVTGeY5kfGmxbjDhd5NigQ>? NHXZXVkyPSCvaX7z NHHHT|lKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGMufGW{bXnuZYwhUGm|L1\MRWcufGGpZ3XkJGhFSUNzIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegRYMueGWydHnk[UBieyC|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDhcoQhdWWjc4Xy[YQh[W[2ZYKgNUBpeixiPUCuNFAxOzcQvF2u MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTFzN{WxO{c,OzFzMUe1NVc9N2F-
Sf9 NXrzN4w6TnWwY4Tpc44h[XO|YYm= NH\IXlMyPSCvaX7z NX65dm44UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEircz30ZYdo\WRiSFTBR|gh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdiQXOtdIVxfGmmZTDhd{B{fWK|dILheIUheHKnaX7jeYJifGWmIH\vdkAyPSCvaX7zJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMTDodkwhRTBwMECxOO69VS5? NIHrdHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGxO|UyPyd-M{GxNVc2OTd:L3G+
Sf9 MUPGeY5kfGmxbjDhd5NigQ>? MmnrNVUhdWmwcx?= MYLJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFjERWMzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIFHjMZBmeHSrZHWgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSC|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEGgbJItKD1yLkCwNVbPxE1w NH7jdIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGxO|UyPyd-M{GxNVc2OTd:L3G+
HCT116 NXXNfZh3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MW[5OkBpenN? M1vncmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJF0xNjByNd88UU4> NWLHUlF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
HCT8 MkX3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MmfoPVYhcHK| MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEigZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiPUCuNFA2|ryPLh?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTFzN{WxO{c,OzFzMUe1NVc9N2F-
U87 M{TaT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHXMN4Q6PiCqcoO= NYXUS4plSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygQVAvODB5zszNMi=> MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
Capan2 NEnVOYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlSwPVYhcHK| M1;4PGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ3HwZY4zKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJF0xNjByN988UU4> MorTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
MDA-MB-453 MkW1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MknXPVYhcHK| NIDHcllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiPUCuNFA6|ryPLh?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTFzN{WxO{c,OzFzMUe1NVc9N2F-
Bel7402 M1nnOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MWS5OkBpenN? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygQVAvODF|zszNMi=> M3HnUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5|MUGxO|UyPzxxYU6=
HepG2 NHv2S3JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXm5OkBpenN? Mn60RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDC9NE4xOTYQvF2u NYniRWlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
NCI-H1299 MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? Mn7nPVYhcHK| M2\HPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyOjl7IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKD1yLkCyOe69VS5? NHTBNnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGxO|UyPyd-M{GxNVc2OTd:L3G+
MCF7 NXu3UmJSSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHztRlU6PiCqcoO= M2ThWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDC9NE4xPDIQvF2u MnXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
HGC27 NW\XdJg6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M4LyXlk3KGi{cx?= NX;kbFRFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIS2MzPyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEA:OC5yNEJOwG0v NVvxVVZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
Sf9 NGXkTFlHfW6ldHnvckBie3OjeR?= MUixOUBucW6| MVjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFjERWMyOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDBZ{1x\XC2aXTlJIF{KHO3YoP0doF1\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIHHu[EBu\WG|dYLl[EBi\nSncjCxJIhzNCB;MD6xN|LPxE1w MnHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
NCI-H460 MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2TnR|k3KGi{cx?= MmraRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEA:OC5zNd88UU4> M2XO[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5|MUGxO|UyPzxxYU6=
SW1990 M1nQNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NETRcpE6PiCqcoO= MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZMUm5NEBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDC9NE4yQM7:TT6= NFTHOWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGxO|UyPyd-M{GxNVc2OTd:L3G+
K562 MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2LCc|k3KGi{cx?= NXrDe3N{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJF0xNjJ6zszNMi=> M1P5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUG3OVE4Lz5|MUGxO|UyPzxxYU6=
Sf9 MmC2SpVv[3Srb36gZZN{[Xl? NGKyT5MyPSCvaX7z MV\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFjERWM1KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIFHjMZBmeHSrZHWgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTVibXnud{Bnd2yub4fl[EBjgSC|dXLzeJJifGViYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEGgbJItKD1yLkS0Oe69VS5? Mm\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
DU145 MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHr4Vmc6PiCqcoO= NHPNV3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJF0xNjV4zszNMi=> MlnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMUe1NVcoRjNzMUG3OVE4RC:jPh?=
HuH7 NVjrR5hESW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYe5OkBpenN? NVj3fmE2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJF0xNjV4zszNMi=> NUPhenNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNVc2OTdpPkOxNVE4PTF5PD;hQi=>
MV4-11 NECxVHJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NGP6W2szPSC2bzC1NEBvVQ>? M3T6b|czKGi{cx?= MkTrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEK1JJRwKDVyIH7NJIFnfGW{IEeyJIhzeyCkeTD0dplxcGGwIHLseYUh[XO|YYm= NVnMU4Q5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{KyNVI4OzBpPkOyNlEzPzNyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AKT / p-AKT / P-p70S6K1 / Ac-H3K9 / p-MEK / p-ERK / p-STAT3 / MCL-1 / Bcl-2 / Bcl-xl / PARP; 

PubMed: 30353642     


Western blots showing protein expression in lysates of MEC-1 cells treated with CUDC-907 at various concentrations or DMSO as a control (0) for 12 h. AKT, p-AKT (Ser473), p-p70S6K (Thr389), Ac-H3K9, ERK, p-ERK (Thr202/Tyr204), p-MEK (Ser217/221), STAT3, p-STAT3 (Tyr705), MCL-1, BCL-2, BCL-xL, and PARP were detected with specific antibodies. β-actin was used as a loading control. 

p-PRAS40 / p-4EBP1 / p-S6 / c-Myc / Cleaved PARP / Caspase-3 / Celaved caspase-3 ; 

PubMed: 28147336     


Western blot analysis demonstrating the effect of increasing concentration of CUDC-907 (from 0.01 to 1 μM) on PI3K downstream targets (p4EBP1, pPRAS40 and pS6) and histone H3 acetylation (Ac Histone H3). The actual inhibition of PI3K and HDAC resulted in a decrease in c-Myc protein levels. Activation of caspase 3 and PARP was present as well. 

SYK / BTK / Bcl-10 / MyD88 / IRAK4 ; 

PubMed: 28147336     


Western blot confirming the effect of CUDC-907 (0.1 μM for 24 hours) on BCR and TLR signaling proteins in B-cell lymphoma cell lines (GCB n = 3 and ABC n = 3).

30353642 28147336
Immunofluorescence
γ-H2AX / 53BP1; 

PubMed: 29760046     


Representative images and quantification of immunofluorescence staining for γH2AX and 53BP1 in SF188 cells treated with radiotherapy (4 Gy), CUDC-907 (100 nmol/L), or combination treatment in which radiotherapy was combined with KU70 siRNA, RAD51 siRNA (48 hours after siRNA transfection), or CUDC-907 (16 hours prior to 4 Gy).

RAD51; 

PubMed: 29760046     


Representative images and quantification of immunofluorescence staining for γH2AX and RAD51 in SF188 cells treated with radiotherapy (4 Gy), CUDC-907 (100 nmol/L), or combination treatment in which radiotherapy was combined with KU70 siRNA, RAD51 siRNA (48 hours after siRNA transfection), or CUDC-907 (16 hours prior to 4 Gy).

29760046
Growth inhibition assay
Cell viability; 

PubMed: 28147336     


MTS assay of 8 representative DLBCL and 2 Hodgkin lymphoma cell lines treated with increasing dose of CUDC-907 from 0.01 to 10 μM for 24, 48, 72 hours. Error bars represent standard error of the mean (S.E.M) of triplicate experiments. 

28147336
体内研究 PI3K/HDAC Inhibitor 口服给药犬类具有生物有效性。PI3K/HDAC Inhibitor 治疗小鼠肿瘤具有长的半衰期。PI3K/HDAC Inhibitor 作用于移植瘤,诱导凋亡,且抑制癌细胞增殖。在高效性研究中, PI3K/HDAC Inhibitor 按最大耐受剂量(MTD)处理,作用于NHL和MM模型,比单独药剂PI3K或HDAC抑制剂参考化合物或两者联用更有效。而且, PI3K/HDAC Inhibitor 按MTD剂量处理,比PI3Kδ选择性抑制剂CAL-101更有效。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:

[1]

- 合并
  • Animal Models: 携带NHL和 MM模型的小鼠
  • Dosages: 100 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 508.55
化学式

C23H24N8O4S

CAS号 1339928-25-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02909777 Recruiting Drug: CUDC-907 Lymphoma|Neuroblastoma|Brain Tumor|Solid Tumor Dana-Farber Cancer Institute|Curis Inc. October 2016 Phase 1
NCT02674750 Completed Drug: CUDC-907 Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations Curis Inc. January 2016 Phase 2
NCT02307240 Completed Drug: CUDC-907 Triple-Negative Breast Cancer|High-grade Serous Ovarian Cancer|Solid Tumors|NUT Midline Carcinoma Curis Inc. November 2014 Phase 1
NCT01742988 Completed Drug: fimepinostat|Drug: Rituximab|Drug: venetoclax Lymphoma|Relapsed Lymphoma|Refractory Lymphoma|Relapsed and/or Refractory Lymphoma|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Double-hit Lymphoma (DHL)|Triple-hit Lymphoma (THL)|Double-expressor Lymphoma (DEL)|High-grade B-cell Lymphoma (HGBL) Curis Inc.|The Leukemia and Lymphoma Society December 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to solve CUDC-907 for in vivo studies (p.o.)?

  • 回答:

    If you decided to take P.O. as your administration route, we suggest you to use 1% CMC-Na to dilute CUDC-907 as a suspension solution for gavage.

  • 问题 2:

    What is the half-life of CUDC-907 in vivo?

  • 回答:

    GUDC-907 is said to have a long half-life in mouse tumor model: http://cancerres.aacrjournals.org/content/72/8_Supplement/3744.short, however, its not formally published and we have no detail of how long it is.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Fimepinostat (CUDC-907) | Fimepinostat (CUDC-907)供应商 | 采购Fimepinostat (CUDC-907) | Fimepinostat (CUDC-907)价格 | Fimepinostat (CUDC-907)生产 | 订购Fimepinostat (CUDC-907) | Fimepinostat (CUDC-907)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID